| 前收市價 | 2.9000 |
| 開市 | 2.8300 |
| 買盤 | 2.7900 x 1400 |
| 賣出價 | 2.8000 x 2200 |
| 今日波幅 | 2.7505 - 2.9100 |
| 52 週波幅 | 1.1000 - 13.2500 |
| 成交量 | |
| 平均成交量 | 1,333,375 |
| 市值 | 291.15M |
| Beta 值 (5 年，每月) | 無 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -3.6100 |
| 業績公佈日 | 2022年5月12日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 2.30 |
- Benzinga
Ginkgo Bioworks Expands Horizontal Synthetic Biology Platform With This Stock Deal
Ginkgo Bioworks Holdings Inc (NYSE: DNA) agreed to acquire Zymergen Inc (NASDAQ: ZY) in an all-stock transaction. Zymergen stockholders will receive 0.9179 shares of Ginkgo's Class A common stock for each Zymergen share. The deal values Zymergen at approximately $300 million and would provide Zymergen shareholders about 5.25% pro forma ownership of Ginkgo. Ginkgo plans to integrate Zymergen's core automation and software technologies for scaling strain engineering capacity into its foundry, incl
- Benzinga
Zymergen Highlights Early Results From Work On Potential COVID-19 Drug Candidate
Zymergen Inc (NASDAQ: ZY) announced early results from its work on infectious disease, discovering several potential novel hits against malaria, tuberculosis, and COVID-19 targets. Hits for PfAPP, a critical target in the treatment of malaria, are now being advanced for validation, with hits for an emerging COVID-19 target, PLpro, expected to follow. The multi-target infectious disease program is supported by a Bill & Melinda Gates Foundation grant, enabling Zymergen to identify novel hits for a
- Insider Monkey
10 Best Biotech Stocks Under $20 in Cathie Wood’s Portfolio
In this article, we discuss the 10 best biotech stocks under $20 in Cathie Wood’s portfolio. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Biotech Stocks Under $20 in Cathie Wood’s Portfolio. ARK Investment Management sits on a portfolio value of nearly $42 billion as of Q3, compared […]
